It is reported that compound 11j (a SMG1 inhibitor) could increase the expression of p53β and p53γ and reactivate the p53 pathway in MDM2-overexpressed or TP53 mutations downstream of exon 9 in tumour cells [11]. Here, SMG1 is linked to neoplasm.